tag:blogger.com,1999:blog-29297569.post6517234172539458971..comments2024-03-26T23:33:33.839-04:00Comments on Notable Calls: Amylin Pharmaceuticals (NASDAQ:AMLN): Upgraded to Overweight at Barclays, target raised to $22notablecallshttp://www.blogger.com/profile/11353264365980606102noreply@blogger.comBlogger1125tag:blogger.com,1999:blog-29297569.post-51754421328211799982009-11-25T17:03:43.305-05:002009-11-25T17:03:43.305-05:00perhaps AMLN would have acted better for the past ...perhaps AMLN would have acted better for the past 15 months if Birchenough hadn't planted the false scare over pancreatitis in the first place. Generally he's a decent analyst but some of his commentary is rather disingenous at best.Unknownhttps://www.blogger.com/profile/00413468335453965212noreply@blogger.com